1
2
#OpenInnovation
3
4
News & Events
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums
June 1, 2022
Intervenn to introduce a glycoproteomic option for liquid biopsies. Read more
Congenica wins Technology Company of the Year
May 12, 2022
Congenica awarded for its cutting-edge genomic platform, which enables the rapid analysis and interpretation of DNA sequencing data. Read more
Imago BioSciences Announces Completion of Enrollment in Phase 2
May 3, 2022
clinical study of bomedemstat for the treatment of essential thrombocythemia with 73 patients enrolled. Read more
5
#knowledgebase
6
7
News & Events
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums
June 1, 2022
Intervenn to introduce a glycoproteomic option for liquid biopsies. Read more
Congenica wins Technology Company of the Year
May 12, 2022
Congenica awarded for its cutting-edge genomic platform, which enables the rapid analysis and interpretation of DNA sequencing data. Read more
Imago BioSciences Announces Completion of Enrollment in Phase 2
May 3, 2022
clinical study of bomedemstat for the treatment of essential thrombocythemia with 73 patients enrolled. Read more
8
Portfolio Highlights
#PharmaBiotech
11
Our View
10
Our Focus
12
#PRI
22
Medical Technologies
#Portfolio
14
Championing
collaborations
that improve health
and the quality of life
for everyone.
#JoinForces
#LifeSciencesInTheFuture
16
Words from
the CEO
17
Portfolio Highlights
#PharmaBiotech
28
Pharmaceutical Biotech
#Portfolio
15
About Us
34
Biorenewables & Others
#Portfolio
19
WHAT'S TRENDING @ XERAYA
InterVenn joins WIN & FNIH Biomarker Consortiums
20
Our Team
21
23
Portfolio Highlights
#Biorenewables
30
Portfolio Highlights
#MedTech
25
26
ARE YOU
The Next
Big Thing?
Submit
A
Proposal
29
36
Career
#Xeraya
35
37
News & Events
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums
June 1, 2022
Intervenn to introduce a glycoproteomic option for liquid biopsies. Read more
Congenica wins Technology Company of the Year
May 12, 2022
Congenica awarded for its cutting-edge genomic platform, which enables the rapid analysis and interpretation of DNA sequencing data. Read more
Imago BioSciences Announces Completion of Enrollment in Phase 2
May 3, 2022
clinical study of bomedemstat for the treatment of essential thrombocythemia with 73 patients enrolled. Read more
32
#agro
33
Portfolio Highlights
#Biorenewables
38
Portfolio Highlights
#MedTech
39
40
Contact Us
41
